Bioequivalence Study of Two Formulations With the Association of Tenofovir 300 mg and Emtricitabine 200 mg.
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Objective: To evaluate the relative bioavailability of a new formulation containing a
combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (T) and compare
this formulation with the branded formulation (R) to meet regulatory criteria for marketing
the test product in Argentina.
Phase:
Phase 1
Details
Lead Sponsor:
Laboratorio Elea Phoenix S.A. Laboratorio Elea S.A.C.I.F. y A.